? The Grand Rapids Clinical Oncology Program (GRCOP) has achieved a national reputation for excellence in community cancer care through its 29-year participation in programs of the National Cancer Institute. In 2003, the GRCOP was highlighted by the NCI as one of 27 CCOPs continuously funded since 1983. The GRCOP comprises a consortium of nine health care systems/hospitals in Western and lower-Northern Michigan and seeks to continue to meet the community's need for innovative and relevant studies of promising therapeutic modalities and cancer controls research. The ongoing mission of the Grand Rapids Clinical Oncology Program is to assure that every person in the region served is provided an opportunity for participation in national cancer prevention and treatment clinical trials. Additionally, we strive to provide education about cancer and the NCI clinical trials program. This grant application encompasses and articulates an ever-expanding vision for the GRCOP. Key strategies to increase patient access and accrual to research protocols include: (1) expansion of on-site screening and patient identification for enrollment in research protocols; (2) development of a targeted clinical trials program for adolescents/young adults; (3) the addition of the Radiation Oncology Therapy Group (RTOG) as a research base, bringing the number of NCI research bases with which the GRCOP affiliates to 8; (4) partnering with NCI in its efforts to increase accrual of the elderly population to clinical trials; and (5) increased involvement by primary care providers and specialty physicians in cancer prevention and control protocols. Strategic initiatives to increase access to and participation in cancer clinical trials by underserved and minority populations incorporate alignment with community organizations throughout the patient catchment area, with an expanding focus on the growing Hispanic/Latino population. Of importance during this upcoming grant cycle will be the GRCOP's continued focus on improving the efficiency and cost-effectiveness of participation in clinical trials through expansion of its data management software system to include both a drug inventory management module and an IRB module. The GRCOP is confident these goals will be accomplished because of the investigators and staff firmly believes that what they do is critically important for present and future oncologic care. The Grand Rapids Clinical Oncology Program represents a proven resource with significant ongoing potential to serve the objectives of the National Cancer Institute's CCOP program. Convinced that our patients are better served by the availability of a strong, quality-oriented community research program, the Grand Rapids Clinical Oncology Program is committed to remaining one of the most successful CCOPs in the country, contributing significantly to oncology clinical research. ? ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
Whitman, Cynthia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Spectrum Health Hospitals
Grand Rapids
United States
Zip Code
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64

Showing the most recent 10 out of 174 publications